Sirnaomics Proposes Termination of 2022 Option Plan, Seeks Shareholder Nod for New 2026 Share Option Scheme

Bulletin Express04-22

Sirnaomics Ltd. announced that its board, meeting after market close on 22 April 2026, will seek shareholder approval to terminate the company’s existing share option scheme adopted on 28 June 2022 and replace it with a new 2026 Share Option Scheme that aligns with the latest Chapter 17 requirements of the Hong Kong Listing Rules.

The existing 2022 scheme, originally set for a 10-year life, will cease to issue new options once terminated; however, all options already granted under that plan will remain valid and exercisable under their original terms. The board confirmed it does not intend to grant further options from the 2022 scheme before the forthcoming general meeting.

The proposed 2026 Share Option Scheme aims to provide a more flexible framework for retaining, incentivising and rewarding eligible participants. Implementation is subject to two conditions: 1. Approval by ordinary resolution at an extraordinary general meeting (EGM) of shareholders. 2. Listing Committee clearance for the listing of, and permission to deal in, shares issued upon exercise of options granted under the new scheme.

A circular outlining full details of the 2026 plan, its principal terms and the EGM notice will be dispatched to shareholders in accordance with Hong Kong Stock Exchange requirements.

Sirnaomics’ board currently comprises one executive director (Dr. Poon Hung Fai), two non-executive directors (Mr. Ouyang Yunlong, Dr. Yin Huijun) and three independent non-executive directors (Mr. Wong Yu Shan Eugene; Dr. Zhang Peng; Ms. Lo Yee Hang).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165040791?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 17:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165040791","market":"hk","top_or_hot":-1,"title":"Sirnaomics Proposes Termination of 2022 Option Plan, Seeks Shareholder Nod for New 2026 Share Option Scheme","media":"Bulletin Express","content":"<p>Sirnaomics Ltd. announced that its board, meeting after market close on 22 April 2026, will seek shareholder approval to terminate the company’s existing share option scheme adopted on 28 June 2022 and replace it with a new 2026 Share Option Scheme that aligns with the latest Chapter 17 requirements of the Hong Kong Listing Rules.</p>\n<p>The existing 2022 scheme, originally set for a 10-year life, will cease to issue new options once terminated; however, all options already granted under that plan will remain valid and exercisable under their original terms. The board confirmed it does not intend to grant further options from the 2022 scheme before the forthcoming general meeting.</p>\n<p>The proposed 2026 Share Option Scheme aims to provide a more flexible framework for retaining, incentivising and rewarding eligible participants. Implementation is subject to two conditions:\n1. Approval by ordinary resolution at an extraordinary general meeting (EGM) of shareholders.\n2. Listing Committee clearance for the listing of, and permission to deal in, shares issued upon exercise of options granted under the new scheme.</p>\n<p>A circular outlining full details of the 2026 plan, its principal terms and the EGM notice will be dispatched to shareholders in accordance with Hong Kong Stock Exchange requirements.</p>\n<p>Sirnaomics’ board currently comprises one executive director (Dr. Poon Hung Fai), two non-executive directors (Mr. Ouyang Yunlong, Dr. Yin Huijun) and three independent non-executive directors (Mr. Wong Yu Shan Eugene; Dr. Zhang Peng; Ms. Lo Yee Hang).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sirnaomics Proposes Termination of 2022 Option Plan, Seeks Shareholder Nod for New 2026 Share Option Scheme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSirnaomics Proposes Termination of 2022 Option Plan, Seeks Shareholder Nod for New 2026 Share Option Scheme\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-22 17:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sirnaomics Ltd. announced that its board, meeting after market close on 22 April 2026, will seek shareholder approval to terminate the company’s existing share option scheme adopted on 28 June 2022 and replace it with a new 2026 Share Option Scheme that aligns with the latest Chapter 17 requirements of the Hong Kong Listing Rules.</p>\n<p>The existing 2022 scheme, originally set for a 10-year life, will cease to issue new options once terminated; however, all options already granted under that plan will remain valid and exercisable under their original terms. The board confirmed it does not intend to grant further options from the 2022 scheme before the forthcoming general meeting.</p>\n<p>The proposed 2026 Share Option Scheme aims to provide a more flexible framework for retaining, incentivising and rewarding eligible participants. Implementation is subject to two conditions:\n1. Approval by ordinary resolution at an extraordinary general meeting (EGM) of shareholders.\n2. Listing Committee clearance for the listing of, and permission to deal in, shares issued upon exercise of options granted under the new scheme.</p>\n<p>A circular outlining full details of the 2026 plan, its principal terms and the EGM notice will be dispatched to shareholders in accordance with Hong Kong Stock Exchange requirements.</p>\n<p>Sirnaomics’ board currently comprises one executive director (Dr. Poon Hung Fai), two non-executive directors (Mr. Ouyang Yunlong, Dr. Yin Huijun) and three independent non-executive directors (Mr. Wong Yu Shan Eugene; Dr. Zhang Peng; Ms. Lo Yee Hang).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02257","symbol_name":"圣诺医药-B","start_time":0,"source_url":"","article_id":"1165040791","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165040791","pubTimestamp":1776851053,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sirnaomics Ltd. announced that its board, meeting after market close on 22 April 2026, will seek shareholder approval to terminate the company’s existing share option scheme adopted on 28 June 2022...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02257":"圣诺医药-B"},"translate_title":"Sirnaomics提议终止2022年期权计划，寻求股东批准新的2026年期权计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02257":1},"content_text":"Sirnaomics Ltd. announced that its board, meeting after market close on 22 April 2026, will seek shareholder approval to terminate the company’s existing share option scheme adopted on 28 June 2022 and replace it with a new 2026 Share Option Scheme that aligns with the latest Chapter 17 requirements of the Hong Kong Listing Rules.\nThe existing 2022 scheme, originally set for a 10-year life, will cease to issue new options once terminated; however, all options already granted under that plan will remain valid and exercisable under their original terms. The board confirmed it does not intend to grant further options from the 2022 scheme before the forthcoming general meeting.\nThe proposed 2026 Share Option Scheme aims to provide a more flexible framework for retaining, incentivising and rewarding eligible participants. Implementation is subject to two conditions:\n1. Approval by ordinary resolution at an extraordinary general meeting (EGM) of shareholders.\n2. Listing Committee clearance for the listing of, and permission to deal in, shares issued upon exercise of options granted under the new scheme.\nA circular outlining full details of the 2026 plan, its principal terms and the EGM notice will be dispatched to shareholders in accordance with Hong Kong Stock Exchange requirements.\nSirnaomics’ board currently comprises one executive director (Dr. Poon Hung Fai), two non-executive directors (Mr. Ouyang Yunlong, Dr. Yin Huijun) and three independent non-executive directors (Mr. Wong Yu Shan Eugene; Dr. Zhang Peng; Ms. Lo Yee Hang).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165040791","isCrawlerRequest":true}